Caricamento...
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at...
Salvato in:
| Pubblicato in: | Diabetes Metab Syndr Obes |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4598200/ https://ncbi.nlm.nih.gov/pubmed/26457056 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S54953 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|